NCT06276764View on ClinicalTrials.gov

The LINFU® U.S. Registry in Patients With IPMN (Intraductal Papillary Mucinous Neoplasm of the Pancreas)

Enrolling by invitationOBSERVATIONAL
Enrollment

500

Participants

Timeline

Start Date

October 15, 2024

Primary Completion Date

September 30, 2034

Study Completion Date

December 1, 2034

Conditions
IPMN, PancreaticPancreas CancerPancreatic Cyst
Interventions
DIAGNOSTIC_TEST

LINFU®

Patients will undergo low intensity non-focused ultrasound excitation of the pancreas for a total of 15 minutes. A contrast agent will be administered IV at five minute intervals. The patient will then receive a dose of secretin and the the patient's pancreatic juice will then be collected for a total of 15 minutes.

Trial Locations (1)

10007

Manhattan Endoscopy Center, New York

All Listed Sponsors
lead

Adenocyte, LLC

INDUSTRY